Navigation Links
China Cord Blood Corporation Reports Third Quarter and First Nine Months of Fiscal 2011 Financial Results
Date:2/28/2011

,637

31,537

4,778Intangible asset, net

26,297

25,569

3,874Available-for-sale equity securities

48,475

50,763

7,691Other investment

-

135,528

20,535Deferred tax assets

288

1,209

183Total assets1,047,034

1,371,778

207,845LIABILITIESCurrent liabilitiesBank loan

45,000

45,000

6,818Accounts payable

5,410

9,569

1,450Accrued expenses and other payables

22,475

21,715

3,290Deferred revenue

36,074

58,242

8,825Amounts due to related parties

2,977

682

103Income tax payable

4,098

8,023

1,216Total current liabilities116,034

143,231

21,702Deferred revenue

93,155

138,328

20,959Other non-current liabilities

15,978

25,121

3,806Deferred tax liabilities

2,259

-

-Total liabilities  227,426

306,680

46,467EQUITYShareholders' equityOrdinary shares - US$0.0001 par value, 250,000,000 shares authorized, 66,743,693 shares and 75,406,875 shares issued and outstanding as of March 31 and December 31, 2010, respectively

46

52

8Additional paid-in capital

719,329

910,316

137,927Accumulated other comprehensive income/(loss)

2,221

(18,992)

(2,878)Retained earnings

87,290

152,734

23,141Total shareholders' equity 808,886

1,044,110

158,198Noncontrolling interests10,722

20,988

3,180Total equity819,608

1,065,098

161,378Total liabilities and equity1,047,034

1,371,778

207,845Exhibit 2CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSFor the Three Months and Nine Months Ended December 31, 2009 and 2010Three months ended December 31,

Nine months ended December 31,2009

2010

200
'/>"/>

SOURCE China Cord Blood Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai
2. China Cord Blood Corporation Forms Zhejiang Subsidiary
3. China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
4. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
5. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
6. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
7. Reportlinker Adds Industrial Biotechnology China News 1011
8. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
9. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011
10. China-Biotics, Inc. to Hold 2010 Annual Meeting of Stockholders on March 9, 2011
11. China Cord Blood Corporation Announces Completion of Warrant Exchange
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... YORK , Sept. 30, 2014 ... and segments with highest potential revenues Do you ... updated report gives you revenue predictions for those ... For those therapies you find financial data, R&D ... analysis you get sales forecasts to 2024 at ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research leader in ... test built upon research from their published P.A.I.N. Study. ... physicians with an objective way to understand theirs patient’s ... individuals. With this new test, physicians will be able ... that will affect their pain tolerance. , The P.A.I.N. ...
(Date:9/30/2014)... 2014 Fast, semi-automatic creation ... in documents ChemAxon , a ... services for life science research, launches ChemCurator, an ... structures from documents. Markush structures are ... generating and understanding Markush structures is a difficult ...
(Date:9/30/2014)... 30, 2014 BioHealth Innovation, Inc. ... biohealth innovations and increasing access to early-stage funding in ... venture capitalist, Tania Fernandez , Ph.D., has joined ... will be a member of the management team for ... to $50 million in seed and early-stage equity investments ...
Breaking Biology Technology:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 2Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 3Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 4Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 5Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... convertible notes, and extended the maturity to 2011 on an additional $23.25 ... ... Cell Therapeutics, Inc.,("CTI" or the "Company") (Nasdaq and MTAX: CTIC) today announced ... "New Notes") due 2011 and 5,459,574 shares of its common stock,no par ...
... Biosciences,Inc. (Nasdaq: NBIX ) announced today that the ... Administration (FDA) indicating,that the New Drug Application (NDA) for ... of insomnia is approvable pending additional clinical and,preclinical data., ... action letter from the FDA,stating that indiplon 5 mg ...
... Company Mails Letter to Shareholders, MONTVALE, N.J., ... today announced that Glass Lewis & Co., one ... that Datascope,shareholders re-elect the Board,s nominees -- James ... Company,s Annual Meeting of Shareholders on,Thursday, December 20, ...
Cached Biology Technology:Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 2Cell Therapeutics, Inc. Announces Issuance of $23.25 Million in New Convertible Senior Notes in Exchange for $36.08 Million of Existing Convertible Senior Subordinated and Subordinated Notes 3Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 2Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 3Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 4Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 5Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 6Glass Lewis Recommends Datascope Shareholders Vote for Re-Election of the Board's Directors 7
(Date:9/30/2014)... engineers, led by Clemson University associate professor Brian ... from the U.S. Department of Energy,s Experimental Program ... positive impact on South Carolina in the advancement ... , "Understanding the scientific and engineering needs for ... nuclear technologies is imperative if South Carolina is ...
(Date:9/30/2014)... DURHAM, N.C. -- Pollution in urban and farm runoff ... a new study finds. , The study, published ... shows that nitrogen in the runoff ends up in ... tumors on the animals, eyes, flippers and internal organs. ... and the National Oceanic and Atmospheric Administration (NOAA) conducted ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
Breaking Biology News(10 mins):Researchers get $5.25 million to advance nuclear technologies in South Carolina 2Pollution linked to lethal sea turtle tumors 2Pollution linked to lethal sea turtle tumors 3Risky metabolism 2
... Research on Aging (Novato, CA) and Biotica Technology Ltd. ... polyketides in diseases of aging. Building on observations that ... Kennedy; Nature 2009), the collaborators will evaluate ... of age-related disease models to identify novel therapeutics. ...
... no crime. Consider that some strains of algae ... the less harmful varieties suck oxygen out of water, ... Recent algal blooms in the Great Lakes, for instance, ... Andr Hudson and colleagues have figured out how to ...
... Cornell University researchers may have solved a 100-year puzzle: ... that therapies to treat Alzheimer,s disease, multiple sclerosis and cancers ... Journal of Neuroscience , Sept. 14, 2011.) , The ... can modulate the entry of large molecules into the brain. ...
Cached Biology News:Buck Institute and Biotica to investigate polyketides in extension of healthy lifespan 2Outsmarting algae -- RIT scientist finds the turn-off switch 2Breaching the blood-brain barrier 2
...
... XT is undoubtedly the most complete and ... concept of layers and subsets makes it ... for different data outputs, for example Cy3 ... as well as different subsets of genes ...
...
...
Biology Products: